Personalis, Inc. (NASDAQ:PSNL) is Blue Water Life Science Advisors LP’s 6th Largest Position

Blue Water Life Science Advisors LP boosted its stake in Personalis, Inc. (NASDAQ:PSNL) by 13.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,132,900 shares of the company’s stock after acquiring an additional 132,900 shares during the period. Personalis accounts for about 5.8% of Blue Water Life Science Advisors LP’s holdings, making the stock its 6th biggest position. Blue Water Life Science Advisors LP owned about 1.60% of Personalis worth $6,548,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp grew its stake in shares of Personalis by 34.5% during the 3rd quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after acquiring an additional 44,900 shares during the period. Jane Street Group LLC boosted its position in Personalis by 154.3% during the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after purchasing an additional 99,671 shares during the period. Barclays PLC boosted its position in Personalis by 45.4% during the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after purchasing an additional 20,444 shares during the period. Geode Capital Management LLC increased its stake in shares of Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after purchasing an additional 83,068 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Personalis in the fourth quarter valued at approximately $63,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Price Performance

Shares of NASDAQ:PSNL opened at $3.19 on Friday. The firm has a fifty day moving average price of $3.94 and a two-hundred day moving average price of $4.56. The company has a market cap of $281.70 million, a price-to-earnings ratio of -1.90 and a beta of 1.89. Personalis, Inc. has a one year low of $1.14 and a one year high of $7.20.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. The company had revenue of $16.80 million during the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Equities research analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Lake Street Capital raised their price objective on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Personalis in a report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price target on shares of Personalis in a research report on Thursday, April 10th. Finally, Craig Hallum assumed coverage on Personalis in a report on Monday, March 17th. They set a “buy” rating and a $8.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.80.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.